SmartDyeLivery

SmartDyeLivery is a clinical-stage biotechnology company based in Germany that specializes in the development of targeted nanocarrier systems for the treatment of organ-specific diseases. The company's proprietary platform utilizes functionalized polymer nanoparticles to deliver active pharmaceutical ingredients directly to specific cell types, such as hepatocytes, thereby increasing efficacy while minimizing systemic side effects. Their lead program, SDL-201, is currently in clinical development for the treatment of sepsis-associated liver dysfunction. By focusing on precision delivery in critical care and inflammatory conditions, SmartDyeLivery aims to address significant unmet medical needs in intensive care medicine.